GLG News by Cosmetic Dermatologists in Private Practice (US)
Articles with lock require a subscription to GLG News |
Request a free trial
February 26, 2007Ceragenix Epiceram product has good potential to be effective in eczema and other skin conditions
Analysis of: Ceragenix Completes Patient Visits for EpiCeram Clinical Study | www.pharmalive.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Ceragenix's new product Epiceram, the Barrier repair cream has potential merit and efficacy comparable to mid strength topical steroids:1. Barrier repair has been found to be antiinflammatory.2. The product in mouse studies has effects comparable to steroid creams.3. The product will have less/ minimal...
February 26, 2007CNTO 1275 will have an impact on the psoriasis market
Analysis of: Centocor, Inc. Releases Phase 2 Data on Novel Biologic CNTO 1275 Targeting Chronic Plaque Psoriasis | pharmalive.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Centocor's product CNTO1275 will have a major and sustained impact on the market:1. Its PASI 75 reduction is better than the current injectables other than Centocor's Infliximab, which requires a complicated IV infusion.2. Side effects are comparable to other agents.3. It is specifically being developed...
February 26, 2007Will the OTC laser hair systems have an impact??
Analysis of: Palomar and Gillette Expand Their Collaboration to Develop and Commercialize an Additional Light-Based Hair Removal Device for Home Use | phx.corporate-ir.net
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Implications:
Palomar and Gillette’s venture in the direct to consumer sale of a light based laser device has several issues that will effect the ability of this venture to be successful
1. The device is only approved for non facial areas, and is only temporarily effective with less than 10% reduction-...
Previous Page : 1 2 3 4 5 6 7 871 to 73 of 73
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Painkiller Risk Found for Heart Patients
www.nytimes.com
FDA Asks if Pain Pill Is Tamper-Proof
online.wsj.com
Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months
www.pipelinereview.com
Hospitals See Drop in Paying Patients
www.nytimes.com
Gardasil, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
www.fiercebiotech.com
Is Celebrex Next ?
November 18, 2008
Will contact lens solutions cost more to ship and store?
November 13, 2008
Economy's impact on healthcare facilities
November 13, 2008
Tamper Proof Narcotic Pain pill? YES
November 13, 2008
A closer look
November 11, 2008